Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RXCKA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Vobramitamab tavatecan
|
|||||
| Synonyms |
IBI129; MGC026
Click to Show/Hide
|
|||||
| Organization |
Innovent Biologics (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-B7H3 antibody
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276); Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Synaffix linker
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
tavatecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|